Clinical Assessment of DAILIES TOTAL1® (DT1) Multifocal

NCT ID: NCT02871375

Last Updated: 2018-07-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-30

Study Completion Date

2016-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate DAILIES TOTAL1® Multifocal (DTl MF) contact lenses in current multifocal contact lens wearers with symptoms of end of day discomfort compared to their habitual multifocal contact lens correction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractive Error

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DT1 MF, then Habitual

Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.

Group Type OTHER

Delefilcon A multifocal contact lenses

Intervention Type DEVICE

Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)

Habitual multifocal contact lenses

Intervention Type DEVICE

Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality

Habitual, then DT1 MF

Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.

Group Type OTHER

Delefilcon A multifocal contact lenses

Intervention Type DEVICE

Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)

Habitual multifocal contact lenses

Intervention Type DEVICE

Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Delefilcon A multifocal contact lenses

Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)

Intervention Type DEVICE

Habitual multifocal contact lenses

Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DAILIES TOTAL1® multifocal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must sign an informed consent document;
* Current daily wearer of soft multifocal contact lenses for at least 6 months with symptoms of contact lens discomfort as defined by the prescreening Eligibility Questionnaire;
* Requires a near spectacle add of +0.50 to +2.50 diopters (D) (inclusive);
* Requires lenses within the power range of study lenses to be fitted;
* Best corrected VA (BCVA) of 20/30 (0.2 logarithmic minimum angle of resolution \[logMAR\]) or better in each eye at distance;
* Willing to wear study lenses for a minimum of 5 days per week, 6 hours per day, and attend all study visits;

Exclusion Criteria

* Any eye condition that contraindicates wearing contact lenses as determined by the Investigator;
* Any use of medications for which contact lens wear could be contraindicated, as determined by the Investigator;
* Monocular (only one eye functional) or fit with only 1 lens;
* Fitted with monovision;
* Prior refractive surgery (e.g., laser vision correction, photorefractive keratectomy, etc.);
* History of herpetic keratitis, ocular surgery, or irregular cornea;
* Currently wearing DT1 MF contact lenses;
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon, a Novartis Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Project Manager, PLS

Role: STUDY_DIRECTOR

Alcon, A Novartis Division

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLE914-P001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.